Skip to main content

Medicine Matters oncology

lung_cancer2

29-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

ALUR, ALEX results cement alectinib as advanced ALK-positive NSCLC standard of care

The findings of the ALUR trial and of an additional analysis of the ALEX trial confirm the benefits of treatment with the second-generation anaplastic lymphoma kinase inhibitor alectinib in patients with advanced ALK-positive non-small-cell lung cancer.

29-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

Hyperprogression not uncommon after immunotherapy in NSCLC patients

Hyperprogression can occur following treatment with agents targeting programmed cell death protein 1 or its ligand, shows a review of patients with advanced non-small-cell lung cancer.

27-09-2017 | Small-cell lung cancer | ESMO 2017 | News

Preliminary lurbinectedin results ‘remarkable’ for relapsed SCLC

Lurbinectedin has potential for the treatment of patients with relapsed small-cell lung cancer as a single agent or in combination with another chemotherapy drug, suggests research reported at the ESMO 2017 Congress in Madrid, Spain.

25-09-2017 | Gastric cancer | ESMO 2017 | News

FLOT4-AIO results could guide operable gastric cancer treatment

Perioperative docetaxel, oxaliplatin, and 5-fluorouracil/leucovorin treatment should be a new standard of care for patients with operable adenocarcinoma of the stomach or gastroesophageal junction, say the FLOT4-AIO trial investigators.

20-09-2017 | Epidemiology | ESMO 2017 | News

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

19-09-2017 | Risk factors | ESMO 2017 | News

Abdominal fat linked to elevated cancer risk

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.

18-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

Dabrafenib–trametinib actively targets BRAF V600E-mutant metastatic NSCLC

Dabrafenib in combination with trametinib provides long-lasting antitumor activity in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer, with a tolerable safety profile, researchers report.

15-09-2017 | Renal cell carcinoma | ESMO 2017 | News

Nivolumab–ipilimumab duo ‘a new standard of care’ in first-line advanced RCC

Phase III trial results presented at the ESMO 2017 Congress support the use of nivolumab plus ipilimumab for the first-line treatment of patients with advanced or metastatic clear-cell renal cell carcinoma.

15-09-2017 | Mesothelioma | ESMO 2017 | News

MAPS2 update supports checkpoint inhibition in relapsed malignant pleural mesothelioma

Treatment with checkpoint inhibitors could be an option for patients with relapsed malignant pleural mesothelioma, say the MAPS2 researchers who reported the survival data of patients given nivolumab alone and alongside ipilimumab.

14-09-2017 | Melanoma | ESMO 2017 | News

Adjuvant nivolumab improves RFS over ipilimumab in metastatic melanoma patients

Patients with resected stage IIIB–IV melanoma derive a significant recurrence-free survival benefit from adjuvant treatment with nivolumab versus ipilimumab, interim results from the CheckMate 238 trial indicate.

13-09-2017 | Cervical cancer | ESMO 2017 | News

Neoadjuvant chemotherapy approach fails to improve locally advanced cervical cancer survival

Concomitant chemoradiation remains the standard of care for women with locally advanced squamous carcinoma of the cervix, following research showing no significant survival advantage with chemotherapy followed by surgery.

Click to watch an interview with surgeon and study author Amita Maheshwari

Read the related comment, by Domenica Lorusso.

12-09-2017 | Urothelial cancer | ESMO 2017 | News

Ramucirumab plus docetaxel prolongs PFS in advanced urothelial cancers

Adding ramucirumab to docetaxel significantly improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, show results from the phase III RANGE trial.

Watch an interview with presenting author Daniel Petrylak here

Lung cancer illustration

12-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

PACIFIC: Durvalumab prolongs PFS in stage III NSCLC patients

Consolidation treatment with the anti-programmed cell death ligand 1 antibody durvalumab improves progression-free survival in patients with stage III, locally advanced, inoperable non-small-cell lung cancer, shows the placebo-controlled PACIFIC trial.

Click here to watch an interview with study author Davey Daniel

3D breast cancer

12-09-2017 | Breast cancer | ESMO 2017 | News

First-line abemaciclib supported for HR+HER2– advanced breast cancer

Results from the MONARCH 3 study give support to first-line use of the oral selective CDK4/6 inhibitor abemaciclib, taken alongside nonsteroidal aromatase inhibitor therapy, in patients with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Click here for an expert comment on the trial.

11-09-2017 | Melanoma | ESMO 2017 | News

Dabrafenib plus trametinib cuts melanoma relapse risk significantly

Adjuvant combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib halves the risk for relapse in patients with stage III melanoma with BRAF V600E or V600K mutations, show results from the COMBI-AD trial.

11-09-2017 | Glioblastoma multiforme | ESMO 2017 | News

Regorafenib improves outcomes in relapsed glioblastoma patients

The phase II REGOMA trial shows that patients with recurrent glioblastoma derive a significant overall survival and disease control benefit from treatment with regorafenib over lomustine.

11-09-2017 | Ovarian cancer | ESMO 2017 | News

ARIEL3 demonstrates maintenance rucaparib benefit for advanced platinum-sensitive ovarian cancer

Maintenance therapy with the PARP inhibitor rucaparib offers significantly longer progression-free survival than placebo for women with advanced platinum-sensitive ovarian cancer, indicate ARIEL3 trial findings reported at the ESMO 2017 Congress in Madrid, Spain.

11-09-2017 | Ovarian cancer | ESMO 2017 | News

No PFS gain with dose-dense weekly chemotherapy in epithelial ovarian cancer

The 3-weekly regimen of carboplatin and paclitaxel should remain the first-line standard of care for women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, say the ICON8 researchers who did not find a progression-free survival benefit with dose-dense weekly chemotherapy.

10-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

Follow-up CT of ‘no benefit’ in the 2 years after complete NSCLC resection

Follow-up computed tomography imaging does not provide a clear survival benefit for patients who undergo complete resection of stage I–III non-small-cell lung cancer, suggests research presented at the ESMO 2017 Congress in Madrid, Spain.

Click here for a video interview with presenter Virginie Westeel

09-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

Osimertinib best in first-line advanced NSCLC setting

Osimertinib significantly improves outcomes relative to gefitinib or erlotinib in treatment-naïve patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer, the phase III FLAURA trial shows.

Watch the interview with study author Suresh Ramalingam